Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Aviragen Therapeutics (AVIR) Reports Q4 Loss of $0.15/Share
August 31, 2017 4:04 PM EDTAviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.15), versus ($0.18) reported last year.
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
... More